Sanofi and Translate Bio are refiling paperwork on their US$3.2 billion merger to give the agency more time to review.
In a Securities and Exchange Commission filing, Translate Bio said that after discussion with the Federal Trade Commission (FTC), Sanofi withdrew and refiled its proposed buyout “in order to provide the FTC with additional time to review the proposed acquisition and information recently provided to them.” Sanofi and Translate Bio struck the buyout deal in early August, and the companies refiled their paperwork August 27 after Sanofi and the FTC held “informal discussions,” the filing stated.
The companies “continue to expect to complete the transaction” subject to any FTC requirements, Translate’s filing stated.
Sanofi and Translate Bio first teamed up on the biotech’s mRNA tech back in 2018, reported Fiercepharma. At the time, Sanofi paid US$45 million to start a three-year partnership that would focus on up to five infectious diseases. Since then, the COVID-19 pandemic has pushed mRNA tech into the global spotlight, and successful vaccines from Moderna and Pfizer-BioNTech are rolling out across the world and generating tens of billions of dollars.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI